This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … more ➔

This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔

The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … more ➔